Integrated In Silico and In Vitro Investigation of Chromene Derivatives as Potential Antidiabetic Agents in 3T3‐L1 Cells
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Ankit Verma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, Delhi, India. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Benzopyrans, Glycoside Hydrolase Inhibitors. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Type 2 diabetes mellitus is characterized by a progressive decline in insulin sensitivity and represents an important therapeutic target for improving glucose homeostasis. Chromen‐derived compounds have attracted interest as potential antidiabetic agents because of their diverse pharmacological activities. Drug‐likeness and pharmacokinetic properties were evaluated using ADME profiling. In silico docking and simulation analyses were performed to characterize ligand–protein interactions and evaluate the stability complex with carbohydrate‐hydrolyzing enzymes. In vitro studies included MTT assay for cell viability/tolerability, α‐glucosidase and α‐amylase inhibition assays and 2‐deoxyglucose (2‐DG) uptake in 3T3‐L1 cells. Conventional RT‐PCR was further performed to assess PI3K and GLUT‐4 mRNA expression. The 2‐DG assay provided a functional measure of cellular glucose uptake under the experimental conditions and was not designed to directly establish insulin sensitization. Both compounds showed favorable predicted drug‐like and pharmacokinetic properties. Docking and MD analyses predicted favorable ligand–enzyme interactions and complex stability. Experimentally, 7‐methoxy‐3‐Phenyl‐4H‐Chromen‐4‐one showed stronger α‐glucosidase inhibition, higher 2‐DG uptake and marked upregulation of PI3K and GLUT‐4 expression, whereas 7,8‐Dihydroxy‐3‐(4‐hydroxyphenyl)‐4H‐chromen downregulated PI3K, modestly increased GLUT‐4 and showed lower 2‐DG uptake. The findings indicate potential antidiabetic activity through complementary effects on carbohydrate digestion and cellular glucose handling. 7‐methoxy‐3‐Phenyl‐4H‐Chromen‐4‐one showed the most consistent response among the chromen derivatives evaluated and emerged as a candidate for further investigation. The present findings do not establish direct activation of insulin‐signaling pathway or reversal of insulin resistance. Comprehensive mechanistic investigations, together with in vivo validation, are needed to further substantiate the therapeutic potential of the compound.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, Delhi, India.
- Department of Pharmaceutical Chemistry, Medicinal Chemistry and Molecular Modelling Lab, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, Delhi, India.
ORCID-Profile: Ankit Verma, Ozair Alam, Manju Sharma
Zitieren
APA
Verma, A., Majumdar, A., Alam, O., & Sharma, M. (2026). Integrated In Silico and In Vitro Investigation of Chromene Derivatives as Potential Antidiabetic Agents in 3T3‐L1 Cells. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70361
Vancouver
Verma A, Majumdar A, Alam O, Sharma M. Integrated In Silico and In Vitro Investigation of Chromene Derivatives as Potential Antidiabetic Agents in 3T3‐L1 Cells. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70361
BibTeX
@article{Verma2026,
author = {Verma, Ankit and Majumdar, Animesh and Alam, Ozair and Sharma, Manju},
title = {Integrated In Silico and In Vitro Investigation of Chromene Derivatives as Potential Antidiabetic Agents in 3T3‐L1 Cells},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70361}
}
EUVIMED